Compare MIRM & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | AROC |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2019 | 1997 |
| Metric | MIRM | AROC |
|---|---|---|
| Price | $91.35 | $26.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $97.55 | $32.40 |
| AVG Volume (30 Days) | 836.6K | ★ 1.2M |
| Earning Date | 02-25-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ 65.71 |
| EPS | N/A | ★ 1.50 |
| Revenue | $471,794,000.00 | ★ $1,439,161,000.00 |
| Revenue This Year | $54.25 | $31.39 |
| Revenue Next Year | $21.09 | $6.64 |
| P/E Ratio | ★ N/A | $17.90 |
| Revenue Growth | ★ 53.66 | 31.94 |
| 52 Week Low | $36.88 | $20.12 |
| 52 Week High | $93.70 | $30.44 |
| Indicator | MIRM | AROC |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 62.45 |
| Support Level | $85.98 | $25.56 |
| Resistance Level | $93.70 | $26.52 |
| Average True Range (ATR) | 3.83 | 0.71 |
| MACD | 0.95 | 0.03 |
| Stochastic Oscillator | 87.40 | 75.58 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Archrock Inc is an energy infrastructure company with a focus on midstream natural gas compression and a commitment to helping customers produce, compress, and transport natural gas. It has two business segments, Contract Operations, and Aftermarket Services. Under the umbrella of contract operations services, the company provides operations to meet customers' natural gas compression needs. Services include designing, owning, installing, operating, and maintaining equipment. Aftermarket Services business provides a full range of services to support the compression needs of customers who own compression equipment, including operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components. It generates maximum revenue from the Contract Operations segment.